Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Oligometastasis
Radiotherapy
Renal cell carcinoma
Stereotatic body radiotherapy
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
04
11
2020
accepted:
15
02
2021
pubmed:
10
3
2021
medline:
1
12
2021
entrez:
9
3
2021
Statut:
ppublish
Résumé
Renal cell carcinoma (RCC) has traditionally been considered radioresistant with a limited role for conventional fractionation as a local approach. Nevertheless, since the appearance of stereotactic body radiation therapy (SBRT), radiotherapy (RT) has been increasingly employed in the management of metastatic RCC (mRCC). The aim of this study was to evaluate the role of SBRT for synchronous and metachronous oligo metastatic RCC patients in terms of local control, delay of systemic treatment, overall survival and toxicity. A Monocentric single institution retrospective data collection was performed. Inclusion criteria were: (1) oligo-recurrent or oligo-progressive disease (less than 5 metastases) in mRCC patients after radical/partial nephrectomy or during systemic therapy, (2) metastasectomy or other metastasis-directed, rather than SBRT not feasible, (3) any contraindication to receive systemic therapy (such as comorbidities), (4) all the histologies were included, (5) available signed informed consent form for treatment. Tumor response and toxicity were evaluated using the response evaluation criteria in solid tumors and the Common Terminology Criteria for Adverse Events version 4.03, respectively. Progression-free survival in-field and out-field (in-field and out-field PFS) and overall survival (OS) were calculated via the Kaplan-Meier method. The drug treatment-free interval was calculated from the start of SBRT to the beginning of any systemic therapy. From 2010 to December 2018, 61 patients with extracranial and intracranial metastatic RCC underwent SBRT on 83 lesions. Intracranial and extracranial lesions were included. Forty-five (74%) patients were treated for a solitary metastatic lesion. Median RT dose was 25 Gy (range 10-52) in 5-10 fractions. With a median follow-up of 2.3 years (range 0-7.15), 1-year in-field PFS was 70%, 2-year in-field PFS was 55%. One year out-field PFS was 39% and 1-year OS was 78%. Concomitant systemic therapy was employed for only 11 (18%) patients, for the others 50 (82%) the drug treatment-free rate was 70% and 50% at 1 and 2 years, respectively. No > G1 acute and late toxicities were reported. The pattern of failure was pre-dominantly out-of-field, even if the population was negatively selected and the used RT dose could be considered palliative. Therefore, SBRT appears to be a well-tolerated, feasible and safe approach in oligo metastatic RCC patients with an excellent in-field PFS. SBRT might play a role in the management of selected RCC patients allowing for a delay systemic therapy begin (one out of two patients were free from new systemic therapy at 2 years after SBRT). Further research on SBRT dose escalation is warranted.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Renal cell carcinoma (RCC) has traditionally been considered radioresistant with a limited role for conventional fractionation as a local approach. Nevertheless, since the appearance of stereotactic body radiation therapy (SBRT), radiotherapy (RT) has been increasingly employed in the management of metastatic RCC (mRCC). The aim of this study was to evaluate the role of SBRT for synchronous and metachronous oligo metastatic RCC patients in terms of local control, delay of systemic treatment, overall survival and toxicity.
PATIENTS AND METHODS
METHODS
A Monocentric single institution retrospective data collection was performed. Inclusion criteria were: (1) oligo-recurrent or oligo-progressive disease (less than 5 metastases) in mRCC patients after radical/partial nephrectomy or during systemic therapy, (2) metastasectomy or other metastasis-directed, rather than SBRT not feasible, (3) any contraindication to receive systemic therapy (such as comorbidities), (4) all the histologies were included, (5) available signed informed consent form for treatment. Tumor response and toxicity were evaluated using the response evaluation criteria in solid tumors and the Common Terminology Criteria for Adverse Events version 4.03, respectively. Progression-free survival in-field and out-field (in-field and out-field PFS) and overall survival (OS) were calculated via the Kaplan-Meier method. The drug treatment-free interval was calculated from the start of SBRT to the beginning of any systemic therapy.
RESULTS
RESULTS
From 2010 to December 2018, 61 patients with extracranial and intracranial metastatic RCC underwent SBRT on 83 lesions. Intracranial and extracranial lesions were included. Forty-five (74%) patients were treated for a solitary metastatic lesion. Median RT dose was 25 Gy (range 10-52) in 5-10 fractions. With a median follow-up of 2.3 years (range 0-7.15), 1-year in-field PFS was 70%, 2-year in-field PFS was 55%. One year out-field PFS was 39% and 1-year OS was 78%. Concomitant systemic therapy was employed for only 11 (18%) patients, for the others 50 (82%) the drug treatment-free rate was 70% and 50% at 1 and 2 years, respectively. No > G1 acute and late toxicities were reported.
CONCLUSION
CONCLUSIONS
The pattern of failure was pre-dominantly out-of-field, even if the population was negatively selected and the used RT dose could be considered palliative. Therefore, SBRT appears to be a well-tolerated, feasible and safe approach in oligo metastatic RCC patients with an excellent in-field PFS. SBRT might play a role in the management of selected RCC patients allowing for a delay systemic therapy begin (one out of two patients were free from new systemic therapy at 2 years after SBRT). Further research on SBRT dose escalation is warranted.
Identifiants
pubmed: 33687659
doi: 10.1007/s12094-021-02574-0
pii: 10.1007/s12094-021-02574-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1717-1726Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
doi: 10.3322/caac.21332
Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol. 1994;12:206–12.
doi: 10.1200/JCO.1994.12.1.206
Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78:1101–6.
doi: 10.1016/j.urology.2011.05.012
Moreira M, Pobel C, Epaillard N, et al. Resistance to cancer immunotherapy in metastatic renal cell carcinoma. Cancer Drug Resist. 2020;3:454–71. https://doi.org/10.20517/cdr.2020.16 .
doi: 10.20517/cdr.2020.16
Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II randomized study. J Clin Oncol. 2019;37(18):1558–65. https://doi.org/10.1200/JCO.19.00201 .
doi: 10.1200/JCO.19.00201
pubmed: 31067138
pmcid: 6599408
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SBRT-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8. https://doi.org/10.1016/S0140-6736(18)32487-5 .
doi: 10.1016/S0140-6736(18)32487-5
pubmed: 30982687
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
doi: 10.1200/JCO.1995.13.1.8
Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–40.
doi: 10.1200/JCO.1999.17.8.2530
Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117:2873–82.
doi: 10.1002/cncr.25836
Van der Poel HG, Roukema JA, Horenblas S, et al. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol. 1999;35:197–203.
doi: 10.1159/000019849
Naito S, Kinoshita H, Kondo T, et al. Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology. 2013;82:846–51.
doi: 10.1016/j.urology.2013.06.035
Zaid HB, Parker WP, Safdar NS, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol. 2017;197:44–9.
doi: 10.1016/j.juro.2016.07.079
Rühle A, Andratschke N, Siva S, Guckenberger M. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol. 2019;26(18):104–12. https://doi.org/10.1016/j.ctro.2019.04.012 .
doi: 10.1016/j.ctro.2019.04.012
Walsh L, Stanfield JL, Cho LC, et al. Efficacy of ablative high-doseper-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol. 2006;50:795–800 (discussion 800).
doi: 10.1016/j.eururo.2006.03.021
Ning S, Trisler K, Wessels BW, et al. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997;80(12 Suppl):2519–28.
doi: 10.1002/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E
Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 1996;34:251–66.
doi: 10.1016/0360-3016(95)02029-2
Franzese C, Franceschini D, Di Brina L, et al. Role of stereotactic body radiation therapy in the management of oligometastatic renal cell carcinoma. J Urol. 2019;201:70–5.
doi: 10.1016/j.juro.2018.08.049
Meyer E, Pasquier D, Bernadou G, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug Group. Eur J Cancer. 2018;98:38–47.
doi: 10.1016/j.ejca.2018.04.008
Ranck MC, Golden DW, Corbin KS, et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013;36:589–95.
doi: 10.1097/COC.0b013e31825d52b2
Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34.
doi: 10.1186/1748-717X-6-34
Stenman M, Sinclair G, Paavola P, Wersall P, Harmenberg U, Lindskog M. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005–2014. Radiother Oncol. 2018;127:501–6.
doi: 10.1016/j.radonc.2018.04.028
Teh B, Bloch C, Galli-Guevara M, et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J. 2007;3:e6.
pubmed: 21614267
pmcid: 3097653
Wersall PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2005;77:88–95.
doi: 10.1016/j.radonc.2005.03.022
Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image guided intensity modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:1744–8.
doi: 10.1016/j.ijrobp.2011.02.040
Svedman C, Sandstrom P, Pisa P, et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45:870–5.
doi: 10.1080/02841860600954875
Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015;54:148–57.
doi: 10.3109/0284186X.2014.939298
Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18:215–22.
doi: 10.1016/j.semradonc.2008.04.001
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer. 2009;45:228.
doi: 10.1016/j.ejca.2008.10.026
Common Terminology Criteria for Adverse EventsCTCAE. Available on 07th/01/2021 at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm .
Kroeze SGC, Fritz C, Schaule J, et al. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU Int. 2020. https://doi.org/10.1111/bju.15284 .
doi: 10.1111/bju.15284
pubmed: 33113260
Zhang Y, Schoenhals J, Christie A, et al. Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys. 2019;105(2):367–75. https://doi.org/10.1016/j.ijrobp.2019.07.023 .
doi: 10.1016/j.ijrobp.2019.07.023
pubmed: 31377159
pmcid: 7647381
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–20. https://doi.org/10.1093/annonc/mdz056 .
doi: 10.1093/annonc/mdz056
pubmed: 30788497
Kato S, Demura S, Murakami H, Tsuchiya H. Surgical metastasectomy for renal cell carcinoma: which patients are the real candidates for surgery? Ann Transl Med. 2019;7(Suppl 8):S273. https://doi.org/10.21037/atm.2019.11.139.PMID:32015992;PMCID:PMC6976505 .
doi: 10.21037/atm.2019.11.139.PMID:32015992;PMCID:PMC6976505
pubmed: 32015992
pmcid: 6976505
Daliani DD, Tannir NM, Papandreou CN, et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2015;104:456.
doi: 10.1111/j.1464-410X.2009.08490.x
Loh J, Davis ID, Martin JM, Siva S. Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncol. 2014;10:76174. https://doi.org/10.2217/fon.14.40 .
doi: 10.2217/fon.14.40
Rühle A, Andratschke N, Siva S, et al. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol. 2019;18:104–12. https://doi.org/10.1016/j.ctro.2019.04.012 .
doi: 10.1016/j.ctro.2019.04.012
pubmed: 31341985
pmcid: 6630187
Motzer RJ, Jonash E, Agarwal N, et al. Kidney cancer, Version 2.2017 NCCN clinical practice guidelines in oncology. J Natl Comp Canc Netw. 2017;15:804.
doi: 10.6004/jnccn.2017.0100
Altoos B, Amini A, Yacoub M, et al. Local control rates of metastatic renal cell carcinoma (rcc) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol. 2015;10:218.
doi: 10.1186/s13014-015-0528-z
Ghia AJ, Chang EL, Bishop AJ, et al. Single fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of phase I/II trials. J Neurosurg Spine. 2016;24(5):829–36.
doi: 10.3171/2015.8.SPINE15844
Briganti A, Montorsi F, Bianchi M, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2011;23:973–80.
pubmed: 21890909
Sheehan JP, Sun MH, Kondziolka D, et al. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 2003;98(2):342–9. https://doi.org/10.3171/jns.2003.98.2.0342 .
doi: 10.3171/jns.2003.98.2.0342
pubmed: 12593621
Dudek AZ, Raza A, Chi M, et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer. 2013;11:155–60.
doi: 10.1016/j.clgc.2012.11.001
Cochran DC, Chan MD, Aklilu M, et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with gamma knife surgery: clinical article. J Neurosurg. 2012;116:978–83.
doi: 10.3171/2012.2.JNS111353
Verma J, Jonasch E, Allen PK, et al. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol. 2013;36:620–4.
doi: 10.1097/COC.0b013e31825d59db
Seastone DJ, Elson P, Garcia JS, et al. Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinoma. Clin Genitourin Cancer. 2014;12:111–6.
doi: 10.1016/j.clgc.2013.10.001
46.Clinicaltrials.gov [Web site]. Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases. Available at: http://clinicaltrials.gov/ct2/show/NCT02978404 , Accessed 10th Jul 2020.
Triggiani L, Alongi F, Buglione M, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017;116:1520.
doi: 10.1038/bjc.2017.103
Jereczek-Fossa BA, Fanetti G, Fodor C, et al. Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: Single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer. 2017;15:e623–32.
doi: 10.1016/j.clgc.2017.01.004
Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27–32.
doi: 10.1016/j.clgc.2012.08.003
Hong JC, Salama JK. The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: what do we know and where are we going? Cancer Treat Rev. 2017;52:22–32.
doi: 10.1016/j.ctrv.2016.11.003
Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019;2(5):515–23. https://doi.org/10.1016/j.euo.2019.05.007 .
doi: 10.1016/j.euo.2019.05.007
pubmed: 31302061